(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 7.5% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Astrazeneca's revenue in 2024 is $47,611,000,000.On average, 4 Wall Street analysts forecast AZN's revenue for 2024 to be $80,277,482,879,885, with the lowest AZN revenue forecast at $78,658,506,984,755, and the highest AZN revenue forecast at $81,307,579,896,326. On average, 4 Wall Street analysts forecast AZN's revenue for 2025 to be $86,556,943,651,791, with the lowest AZN revenue forecast at $85,093,216,543,654, and the highest AZN revenue forecast at $87,369,080,052,203.
In 2026, AZN is forecast to generate $91,455,879,194,185 in revenue, with the lowest revenue forecast at $89,402,606,637,429 and the highest revenue forecast at $93,171,535,631,975.